Background: Venous thromboembolism (VTE) is a common complication among patients
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and …

Venous thromboembolism (VTE) is a significant health problem in the general population
but especially in cancer patients. In this review, we discuss the epidemiology and burden of …

Background Ambulatory patients receiving systemic cancer therapy are at varying risk for
venous thromboembolism. However, the benefit of thromboprophylaxis in these patients is …

Platelets play significant and varied roles in cancer progression, as detailed throughout this
review series, via direct interactions with cancer cells and by long-range indirect interactions …

Cancer-associated venous thrombosis is a common condition, although the reported
incidence varies widely between studies depending on patient population, start and duration …

Background Plasma and other body fluids contain membranous extracellular vesicles (EVs),
which are considered to derive from activated or apoptotic cells. EVs participate in …

Purpose To provide recommendations about prophylaxis and treatment of venous
thromboembolism (VTE) in patients with cancer. Prophylaxis in the outpatient, inpatient, and …

Extracellular vesicles (EVs), including exosomes, microvesicles, and apoptotic bodies, are
released by almost all cell types, including tumour cells. Through transfer of their molecular …

The heparins, well-known for their anticoagulant properties, may also have anti-
inflammatory effects that could contribute to their effectiveness in the treatment of venous …

Patients with cancer have an increased risk for venous thrombosis. Interestingly, different
cancer types have different rates of thrombosis, with pancreatic cancer having one of the …